IQVIA™ Real-World Insights Bibliography

Use of maximum medical therapy in primary open-angle glaucoma: a retrospective, electronic medical records-based study from the UK
Author(s): Costa VP1, Durus A2, Gondos A3, Bezlyak V2, Wintermantel T3, Sagkriotis A2, Hubatsch D4, Kim YS2
Affiliations(s): 1: Department of Ophthalmology, University of Campinas, Sao Paulo, Brazil; 2: Novartis Pharma AG, Basel, Switzerland; 3: Real World Insights, IQVIA, Basel, Switzerland; 4: Novartis Pharmaceutical Corporation Inc, Fort Worth, TX, USA
Publication(s):  Wolrd Glaucoma Congress, Melbourne, Australia, 27-30 March 2019
Document Type(s): Poster,
Countries: UK,
C:
Y:
Ophthalmology,
2019
  L:
A:
English
clinical setting: Secondary care, Epidemiological study, Retrospective database analysis,
  Add to report
 
 
Association between changes in anatomical and functional outcomes and physicians? decisions to treat patients with licensed anti-VEGFs for neovascular age-related macular degeneration in the UK
Author(s): Chakravarthy U1, Kap E2, Pillai N2, Syntosi A3, Sagkriotis A3
Affiliations(s): 1. Centre for Experimental Medicine, Institute of Clinical Science, Queen's University Belfast, Belfast, UK; 2. IQVIA, Switzerland, Germany; 3. Novartis Pharma AG, Basel, Switzerland
Publication(s):  19th EURETINA Congress, Paris, France, 5-8 September 2019
Document Type(s): Oral presentation,
Countries: UK,
C:
Y:
Ophthalmology,
2019
  L:
A:
English
clinical setting: Secondary care, Epidemiological study, Observational study, Retrospective database analysis,
  Add to report
 
 
Drug utilization and associated visual acuity in patients treated with anti-VEGFs for neovascular age-related macular degeneration (nAMD) in the UK
Author(s): Sagkriotis A1, Bennett N2, Skelly A1, Venkatesan S3, Oyetunde S2
Affiliations(s): 1. Novartis Pharma AG, Basel, Switzerland; 2. Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom; 3. IQVIA Real World Insights, UK
Publication(s):  19th EURETINA Congress, Paris, France, 5-8 September 2019
Document Type(s): Poster,
Countries: UK,
C:
Y:
Ophthalmology,
2019
  L:
A:
English
clinical setting: Secondary care, Epidemiological study, Observational study, Retrospective database analysis,
  Add to report
 
 
Long term treatment patterns and visual outcomes of anti-vascular endothelial growth factor agents among people with neovascular age-related macular degeneration in the US
Author(s): Skelly A1, Khanani AM2, Griner R3, Bezlyak V1, Clark J4, Sagkriotis A1
Affiliations(s): 1. Novartis Pharma AG, Basel, Switzerland; 2. Sierra Eye Associates, Reno, Nevada, USA; 3. IQVIA, Cambridge, MA, US; 4. Novartis Pharmaceuticals, East Hanover, NJ, US
Publication(s):  ARVO, Vancouver, Canada, April 28 - May 2 2019
Document Type(s): Poster,
Countries: USA,
C:
Y:
Ophthalmology,
2019
  L:
A:
English
clinical setting: Secondary care, Epidemiological study, Observational study, Retrospective database analysis,
  Add to report
 
 
Clinical effectiveness of switching between ranibizumab and aflibercept in treatment of neovascular AMD: US real-world outcomes
Author(s): Dugel PU1, Griner R2, Ferreira A3, Milnes F3, Lotery AJ4
Affiliations(s): 1. Retinal Consultants of Arizona LTD, Retinal Research Institute LLC, Phoenix, AZ, USA; 2. IQVIA Real World Solutions, USA; 3. Novartis Pharma AG, Basel, Switzerland; 4. Eye Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK
Publication(s):  J Vitreoretin Dis. 2019 3(3):127-134
Document Type(s): Article,
Countries: USA,
Click here for the abstract
C:
Y:
Ophthalmology,
2019
  L:
A:
English
clinical setting: Secondary care, Epidemiological study, Observational study, Retrospective database analysis,
  Add to report
 
 
Treat and extend treatment interval patterns with anti-VEGF therapy in nAMD patients
Author(s): Skelly A1, Bezlyak V1, Liew G2, Kap E3, Sagkriotis A1
Affiliations(s): 1. Novartis Pharma AG, 4002 Basel, Switzerland; 2. Westmead Institute for Medical Research, University of Sydney, Westmead NSW 2145, Australia; 3. IQVIA Commercial GmbH & Co. OHG, 60549 Frankfurt, Germany
Publication(s): 
Document Type(s): Article,
Countries: Australia,
Click here for the abstract
C:
Y:
Ophthalmology,
2019
  L:
A:
English
clinical setting: Secondary care, Epidemiological study, Observational study, Retrospective database analysis,
  Add to report
 
 
Anti-VEGF persistence and switching in nAMD: real world analysis from a Canadian claims database
Author(s): Tina Maio-Twofoot 1, Alexandros Sagkriotis 2, Atif Kukaswadia 3, Fran?ois Lebeau 1, Valerie Gregory 1
Affiliations(s): 1 Novartis Pharmaceuticals Canada Inc., 2 Novartis Pharma AG; 3 IQVIA
Publication(s): 
Document Type(s): Poster,
Countries: Canada,
C:
Y:
Ophthalmology,
2019
  L:
A:
English
Longitudinal study, Observational study, Retrospective database analysis,
  Add to report
 
 
Anti-VEGF dosing intervals in patients with neovascular age-related macular degeneration: a retrospective cohort study in Australia
Author(s): Skelly A1, Rodriguez Torres L1, Griner R2, Bezlyak V1, Kap E2, Sagkriotis A1
Affiliations(s): 1 Novartis Pharma AG, Basel, Switzerland 2 IQVIA, Cambridge, Massachusetts, USA 3 IQVIA, Frankfurt, Germany
Publication(s):  International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting, 2018, Baltimore, US
Document Type(s): Poster,
Countries: USA,
C:
Y:
Ophthalmology,
2018
  L:
A:
English
Epidemiological study, Observational study, Retrospective cohort analysis,
  Add to report
 
 
Identifying the confuonders that explain the difference in readouts between non-interventional and randomized controlled trials: the case of treatments in neovascular age-related macular degeneration
Author(s): Sakriotis A1, Griner R2, Durus A1, Doyle OM2, Rodriguez-Torres L1, Wintermantel T2, Clemens A13
Affiliations(s): 1. Novartis Pharma AG, Basel, Switzerland; 2. IQVIA Real World Insights, Switzerland/UK/US; 3. Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany
Publication(s):  ISPOR Europe, Barcelona, Spain, 10-14 November 2018
Document Type(s): Poster,
Countries: Australia, UK, USA,
C:
Y:
Ophthalmology,
2018
  L:
A:
English
clinical setting: Secondary care, Epidemiological study, Observational study, Retrospective database analysis,
  Add to report
 
 
Incidence of Nd:YAG capsulotomy following single-piece monofocal acrylic IOLs implantation: a retrospective real world evidence study in the UK
Author(s):  Mukesh Dhariwal, Christine Bouchet, Derek OBoyle, Javeed Khan, Alessandra Venerus, Anushini Muthutantri
Affiliations(s): "1GlaxoSmithKline, Brentford, Middlesex, UK 2Current affiliation: Evalueserve Life Sciences Healthcare, London, UK 3Scientific Computing Group, Sheffield Teaching Hospitals Foundation Trust, Sheffield, UK 4IQVIA, London, UK 5Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK 6National Pulmonary Hypertension Service (Sheffield), Sheffield Pulmonary Vascular Unit, Royal Hallamshire Hospital, Sheffield, UK 7INSIGNEO, University of Sheffield, Sheffield, UK" 1 Queen?s University of Belfast Royal Victoria Hospital, Belfast, Ireland 2 University Hospitals Bristol National Health Service Foundation Trust, Bristol, United Kingdom 3 Gloucestershire Eye Unit, Cheltenham General Hospital, Cheltenham, United Kingdom 4 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom 5 Department of Ophthalmology, UC Davis Medical Center, Sacramento, CA, USA 6 Genentech, Inc., South San Francisco, CA, USA Alcon, Novartis, IQVIA
Publication(s): 
Document Type(s): Poster,
Countries: UK,
C:
Y:
Ophthalmology,
2018
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
 1 of 11 Next Page Last Page